Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Ponatinib hydrochloride
Drug ID BADD_D01800
Description Ponatinib is a novel Bcr-Abl tyrosine kinase inhibitor that is especially effective against the T315I mutation for the treatment of chronic myeloid leukemia. FDA approved on December 14, 2012.
Indications and Usage Ponatinib is indicated for the treatment of adult patients with chronic phase, accelerated phase, or blast phase chronic myeloid leukemia (CML) that is resistant or intolerant to prior tyrosine kinase inhibitor therapy or Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ALL) that is resistant or intolerant to prior tyrosine kinase inhibitor therapy.
Marketing Status Prescription
ATC Code L01EA05
DrugBank ID DB08901
KEGG ID D09951
MeSH ID C545373
PubChem ID 46908927
NDC Product Code 63020-536; 63020-533; 42973-242; 63020-535; 63020-534; 48957-0070
Synonyms ponatinib | 3-(2-(imidazo(1,2-b)pyridazin-3-yl)ethynyl)-4-methyl-N-(4-((4-methylpiperazin-y-1-yl)methyl)-3-(trifluoromethyl)phenyl)benzamide | ponatinib hydrochloride | AP24534 | AP-24534 | AP 24534 | Iclusig
Chemical Information
Molecular Formula C29H28ClF3N6O
CAS Registry Number 1114544-31-8
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Abdominal discomfort07.01.06.001--Not Available
Abdominal pain07.01.05.002--
Abdominal pain lower07.01.05.010--Not Available
Abdominal pain upper07.01.05.003--
Alanine aminotransferase increased13.03.01.003--
Amylase increased13.05.01.009--
Aphthous ulcer07.05.06.002--Not Available
Arrhythmia02.03.02.001--Not Available
Aspartate aminotransferase increased13.03.01.006--
Asthenia08.01.01.001--Not Available
Atrial fibrillation02.03.03.002--
Back pain15.03.04.005--
Blood albumin decreased13.09.01.001--Not Available
Blood bicarbonate decreased13.11.01.019--
Blood bilirubin increased13.03.01.008--
Blood calcium decreased13.11.01.002--Not Available
Blood calcium increased13.11.01.003--Not Available
Blood creatinine increased13.13.01.004--
Blood glucose decreased13.02.02.001--Not Available
Blood glucose increased13.02.02.002--Not Available
Blood potassium decreased13.11.01.010--Not Available
Blood potassium increased13.11.01.011--Not Available
Blood sodium decreased13.11.01.012--Not Available
Blood sodium increased13.11.01.013--Not Available
Blood triglycerides increased13.12.03.001--Not Available
Bone pain15.02.01.001--
Burning sensation17.02.06.001; Available
The 1th Page    1 2 3 4 5    Next   Last    Total 5 Pages